替吉奥联合贝伐珠单抗治疗晚期胃癌疗效分析

Effect of S-1 combined with bevacizumab in the treatment of advanced gastric cancer

目的探讨替吉奥联合贝伐珠单抗治疗晚期胃癌效果的分析。方法收集佳木斯市肿瘤医院2019年1月至2021年12月间的94例晚期胃癌患者,随机分为对组和观察组,对照组47例,观察组47例。对照组实行单药替吉奥化学治疗,观察组给予替吉奥联合贝伐珠单抗治疗,两组均治疗6个周期,每个周期21 d。比较两组治疗效果。结果与对照组相比,观察组CA199、CEA、MMP-9表达水平[分别为(54.22±6.03)、(21.16±3.78)、(205.53±9.65)]显著降低(P<0.05)、EORTC生活质量问卷(QLQ-C30)评估[分别为社会功能(79.40±15.11)、心理功能(79.54±14.10)、躯体疼痛(76.32±12.15)、物质生活(73.23±11.38)]显著提高(P<0.05)、不良事件(AE)发生率(4.26%)显著降低(P<0.05)。结论胃癌晚期患者中使用替吉奥联合贝伐珠单抗治疗,可以降低CA199、CEA、MMP-9表达水平缓解临床症状以及提高生活质量、治疗效果,降低不良事件发生率。

Objective To analyze the effect of S-1 combined with bevacizumab in the treatment of gastric cancer stage IV.Methods A total of 94 patients with stage IV gastric cancer in Jiamusi Cancer Hospital from 2019 to 2021 were randomly divided into control group and observation group,with 47 cases in each group.The control group was treated with single-drug S-1 chemotherapy,while the observation group was treated with S-1 combined with bevacizumab.Both groups were treated for 6 cycles,with each cycle lasting 21 days.The therapeutic effects of the two groups were compared.Results Compared with the control group,the expression levels of CA199,CEA and MMP-9 in the observation group were(54.22±6.03),(21.16±3.78)and(205.53±9.65),respectively,which were significantly reduced(P<0.05).The evaluation results of EORTC Quality of Life Questionnaire(QLQ-C30)showed that the social function(79.40±15.11),psychological function(79.54±14.10),physical pain(76.32±12.15)and material life condition(73.23±11.38)were significantly improved(P<0.05),and the incidence of adverse events(AE)was 4.26%,which was significantly reduced(P<0.05).Conclusion In the clinical treatment of patients with advanced gastric cancer,S-1 combined with bevacizumab can reduce the expression levels of CA199,CEA and MMP-9,relieve clinical symptoms,improve the quality of life,improve the therapeutic effect and reduce the incidence of adverse events.